Summary & Overview
HCPCS J9341: Thiotepa (Tepylute) Injection, 1 mg
HCPCS Level II code J9341 denotes the injectable antineoplastic agent thiotepa (Tepylute) billed per 1 mg unit. This code is used when thiotepa is supplied and administered as part of chemotherapy regimens across ambulatory infusion centers, hospital outpatient departments, and oncology clinics. Nationally, accurate coding for high-cost oncology drugs like thiotepa affects billing consistency, coverage determinations, and payment integrity for both commercial payers and government programs.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise presentation of what J9341 represents clinically and operationally, how major payers commonly approach coverage and billing for unit-dose oncology injectables, and where to look for policy or documentation drivers that influence reimbursement outcomes. The publication outlines benchmarks for typical billing units and common modifiers used in practice when available, and summarizes clinical context surrounding thiotepa administration without providing clinical guidance. Data not available in the input is identified where applicable. This provides a national-level reference for coding professionals, billing staff, and policy analysts working with oncology drug administration claims.
Billing Code Overview
HCPCS Level II code J9341 describes the injection of thiotepa (Tepylute), 1 mg. This code represents a single-unit drug administration for an antineoplastic agent supplied for injection. The service type is drug administration/injectable chemotherapy. The typical site of service for this administration is an outpatient infusion center, hospital outpatient department, or oncology clinic where parenteral chemotherapy agents are administered.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with advanced bladder cancer is scheduled to receive intravesical chemotherapy with J9341 (thiotepa) administered as an injection preparation measured per 1 mg. The clinical workflow begins with a pre-procedure oncology clinic visit where the oncologist documents indication, consent, prior therapies, and baseline labs (CBC, renal and hepatic panel). On the day of treatment the patient presents to an outpatient oncology infusion center or ambulatory surgery center; typical site of service is an outpatient infusion suite or clinic allowing topical, intravesical, or intravenous administration depending on indication. Pharmacy compounds the required dose of J9341 under sterile conditions and performs labeling and verification. Nursing performs medication reconciliation, confirms patient identity and allergies, and establishes intravenous access or instillation route as clinically indicated. The medication is administered per protocol; monitoring for adverse reactions (local irritation, myelosuppression, chemical cystitis if intravesical) occurs during and after administration. Documentation includes drug name, NDC and HCPCS J9341 with total mg administered, route, lot number, start and stop times, any concurrent medications, and applicable modifier(s). Billing reflects the exact milligram quantity billed using J9341 units, appropriate place of service, and any modifiers for circumstances such as discontinued services, professional component, or split/shared services.
Coding Specifications
| Modifier | Description | When to Use |
|---|